Dilevalol: a selective beta-2 adrenergic agonist vasodilator with beta adrenergic blocking activity

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Clinical Trials

Background:

• Dilevalol is the R-R' optical isomer of labetalol.
• It exhibits distinct pharmacological properties, including increased potency as a beta-2 agonist and beta antagonist, with minimal alpha antagonist activity.

Purpose of the Study:

• To evaluate the efficacy and safety of dilevalol as an antihypertensive agent.
• To compare dilevalol's effects with placebo and other beta-blockers (propranolol, metoprolol, atenolol).

Main Methods:

• Prospective, double-blinded clinical trials were conducted.
• Hemodynamic studies assessed blood pressure, systemic vascular resistance, cardiac index, and heart rate.
• Effects on left ventricular hypertrophy and renal function were evaluated.

Main Results:

• Dilevalol effectively reduces blood pressure by decreasing systemic vascular resistance, with a slight decrease in heart rate and no change in cardiac index.
• It demonstrated efficacy for 24-30 hours with a half-life of 15-18 hours.
• Dilevalol showed regression of left ventricular hypertrophy in younger individuals, improved left ventricular performance, and had no adverse effects on renal function.

Conclusions:

• Dilevalol is an effective antihypertensive agent with a favorable side effect profile.
• It exhibits a particularly low incidence of central nervous system side effects compared to other agents.
• Dilevalol offers a promising therapeutic option for hypertension management.